Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Authors
Sukjun Kim (ORCID: https://orcid.org/0000-0002-3190-9829)
Jung Eun Lee (ORCID: https://orcid.org/0009-0009-7608-0709)
Nam Suk Sim (ORCID: https://orcid.org/0000-0002-5567-8076)
Dahee Kim (ORCID: https://orcid.org/0000-0001-7286-1334)
Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Sukjun Kim, Jung Eun Lee, Nam Suk Sim, Dahee Kim et al.
Local Database Links
2 links
Topics
Head and Neck Cancer Studies
article
Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Sukjun Kim, Jung Eun Lee, Nam Suk Sim, Dahee Kim, Min Hee Hong, Yoojoo Lim, Sun Och Yoon, Junha Cha, Chiyoon Oum, Insuk Lee, Hyunwook Kim, Chaeyeon Kim, Heon Song, Goeun Park, Chan‐Young Ock, Hye Ryun Kim, Hyun Jun Hong, Chang Gon Kim, Yoon Ji Bang, Seunghee Kim‐Schulze, Mingu Kang, Gamin Kim, Heejung Park, Se‐Heon Kim, Brian Hyohyoung Lee, Dawoon Han, Miriam Mérad, Geoffrey Kelly, Yoon Woo Koh, Jong Hoon Kim, Inkyung Jung, Chang Geol Lee, Hyun Je Kim, Jin Woo Park, Kyung Hwan Kim, Young Min Park, Seulki Kim